| scholarly article | Q13442814 |
| P50 | author | Hamed Fakhim | Q40035085 |
| Hamid Badali | Q40035132 | ||
| Anuradha Chowdhary | Q42337778 | ||
| Jacques F. Meis | Q51269909 | ||
| Eric Dannaoui | Q56458995 | ||
| Afsane Vaezi | Q59036519 | ||
| P2093 | author name string | Anupam Prakash | |
| P2860 | cites work | Multidrug-resistant endemic clonal strain of Candida auris in India. | Q39092162 |
| The first cases of Candida auris candidaemia in Oman | Q39092264 | ||
| In Vitro Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of Candida Species. | Q40034825 | ||
| Echinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients. | Q40448192 | ||
| In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. | Q41810114 | ||
| Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories? | Q42326663 | ||
| Candida auris-associated candidemia, South Africa | Q42712931 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. | Q47643534 | ||
| Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016. | Q50985111 | ||
| In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. | Q53789385 | ||
| Synergy, antagonism, and what the chequerboard puts between them | Q73521098 | ||
| Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods | Q84844536 | ||
| Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia | Q28818814 | ||
| Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. | Q30834974 | ||
| Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally | Q33704302 | ||
| New clonal strain of Candida auris, Delhi, India | Q34372060 | ||
| ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections | Q34376097 | ||
| First hospital outbreak of the globally emerging Candida auris in a European hospital | Q34543358 | ||
| Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses | Q34547546 | ||
| Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek | Q35586995 | ||
| Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata | Q35806170 | ||
| Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations | Q35941237 | ||
| Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations | Q36364100 | ||
| Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006 | Q36424929 | ||
| Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr | Q37036246 | ||
| Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel | Q37664411 | ||
| Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. | Q38711698 | ||
| Candida auris candidaemia in Indian ICUs: analysis of risk factors | Q38883902 | ||
| The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. | Q38949297 | ||
| Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. | Q39092102 | ||
| Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. | Q39092125 | ||
| First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia | Q39092138 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| Candida auris | Q26816853 | ||
| P577 | publication date | 2017-10-24 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In Vitro Interactions of Echinocandins with Triazoles Against Multidrug-Resistant Candida auris | |
| P478 | volume | 61 |
| Q64972797 | A Predominance of Clade 17 Candida albicans Isolated From Hemocultures in a Tertiary Care Hospital in Thailand. |
| Q90618019 | Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus |
| Q58822253 | Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities |
| Q49988058 | Candida auris: a Review of the Literature. |
| Q92320618 | Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris |
| Q50128552 | Containment strategies to address the expanding threat of multidrug-resistant Candida auris |
| Q99709014 | Echinocandins as Biotechnological Tools for Treating Candida auris Infections |
| Q92376812 | Effects of the Natural Peptide Crotamine from a South American Rattlesnake on Candida auris, an Emergent Multidrug Antifungal Resistant Human Pathogen |
| Q57294706 | Evaluation of a new matrix-assisted laser desorption/ionization time-of-flight mass spectrometry system for the identification of yeast isolation |
| Q64084323 | Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen |
| Q90573021 | In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism |
| Q104135019 | In vitro synergy of isavuconazole in combination with colistin against Candida auris |
| Q92075140 | Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris |
| Q58772251 | Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside |
| Q58788401 | Successful treatment of shunt infection with intraventricular caspofungin |
Search more.